Schedule 13G ownership disclosure

Forte Biosciences Inc

Common Stock, par value $0.001 per share · CUSIP: 34962G208

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • ORBIMED ADVISORS LLC

    Shares: 510,000.00 · Class: 8%

  • ORBIMED CAPITAL LLC

    Shares: 90,000.00 · Class: 1.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-25-000158
Form type
SCHEDULE 13G
Filer
Forte Biosciences, Inc.
CIK
CIK 1419041
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub